Eclipsebio Launches eRibo™ for Improved Methods to Profile Protein Translation; Technology Details Will Be Presented at Keystone Symposia

Optimized ribosomal profiling technologies, under Eclipsebio’s eRibo™ product family, are now commercially available for faster and easier acquisition of ribosomal occupancy data to study protein translation

SAN DIEGO, January 31, 2023 – Eclipse Bioinnovations (Eclipsebio), a leading RNA genomics company developing and commercializing novel, data-driven technologies that interrogate RNA, today announced the launch of its eRibo™ suite of technologies, providing methods that improve upon differential expression analysis compared to the traditional Ribo-Seq. Details on how eRibo works and its capabilities will be shared in a poster presentation and a workshop at the Keystone Symposia on Molecular & Cellular Biology: Protein RNA Interactions Meeting, taking place from January 29 to February 1 in Vancouver, British Columbia.

“We are excited to announce that our customers can now benefit from our eRibo technology to improve their research on protein translation,” said Eclipsebio CEO and cofounder Peter Chu, Ph.D. “Scientists interested in determining changes in protein translation will benefit from using this method and will be able to explore ribosome profiling in a faster, easier way than when using traditional Ribo-Seq technologies or shotgun proteomics.”

The eRibo product family consists of:

    • eRibo 3’ that delivers a rapid, easy, and efficient approach to count ribosome-associated polyadenylated transcripts and gene-level ribosome occupancy
    • eRibo Total that allows the study of transcriptome-wide ribosome occupancy while enabling the interrogation of splicing events

Presentation Information:

  • Poster Session 2: Tuesday, January 31, 7:30 PM PST
    Maya Kunkel, Ph.D., Principal Scientist at Eclipsebio
    eRibo: A Simplified and Robust Method for Profiling Protein Translation
    Poster #2021
  • Workshop 2 (J8): Wednesday, February 1, 2:30 PM PST
    Eric Van Nostrand, Ph.D., co-founder of Eclipsebio and assistant professor at Baylor College of Medicine, Houston
    Characterizing RNA Binding Protein-Mediated Regulation of Transcription with ribo-eCLIP

About Eclipsebio’s RNA Genomics Platform and Products

Eclipsebio’s comprehensive RNA genomics platform is poised to build the world’s most detailed multi-dimensional RNA maps through transcriptome-wide views of RNA interactions with RNA binding proteins (RBP-eCLIP™), RNA modifications such as m6A (m6A-eCLIP™), alternative transcription start site and polyadenylation site usage (EndSeq™), and microRNA-mRNA interactions (miR-eCLIP™), profile translation (eRibo™) and probe RNA structure (eSHAPE).

About Eclipsebio

Eclipsebio is a private biotechnology company developing first-in-class technologies to enable faster and more effective development of RNA therapeutics. The company offers its end-to-end RNA genomics products as services and kits and also provides custom RNA genomics services for select partners. Eclipsebio is headquartered in San Diego. For more info, visit www.eclipsebio.com.

Contacts

Company Contact: Peter Chu, Ph.D., CEO, info@eclipsebio.com, +1.858.255.8115
Media Contact: Jessica Yingling, Ph.D., Little Dog Communications Inc.jessica@litldog.com, +1.858.344.8091

Related articles

Press Release

07
27
23

Eclipsebio Launches eRibo Pro™, a Ribosome Profiling Service to Obtain RNA Translation Data

Eclipsebio is the exclusive license holder to patents covering key aspects of Ribo-Seq technology developed by inventors Weismann and Ingolia at the University of California, San Fransisco (UCSF) SAN DIEGO, July 27, 2023 /PRNewswire/ — Eclipsebio, a leading provider of innovative RNA analysis solutions, announces the launch of its proprietary eRibo Pro™ service, an all-inclusive offering to […]

read more

Press Release

07
05
23

Eclipsebio to Present Data and Unveil Antibody Barcode CLIP, a Novel Multiplexed CLIP Technology, at the RNA Society Annual Meeting 2022

Data selected for an oral presentation demonstrates the multiplex ability of Antibody Barcode CLIP to perform transcriptome-wide interrogation of binding sites between RNA and RNA binding proteins SAN DIEGO, May 24, 2022 /PRNewswire/ — Eclipse Bioinnovations, Inc. (Eclipsebio), the leading RNA genomics company developing and commercializing novel, data-driven technologies that interrogate RNA, today announced the presentation of data describing […]

read more

Press Release

02
07
23

Eclipsebio Launches eSHAPE™ Product Family to Provide RNA Structure Probing at AGBT 2023

Eclipsebio Launches eSHAPE™ Product Family to Provide RNA Structure Probing at AGBT 2023 Eclipsebio’s eSHAPE™ product family is a combination of kits, services, and databases, that facilitates the study of RNA secondary structure in both in vitro and in cellulo conditions SAN DIEGO, February 7, 2023 – Eclipse Bioinnovations (Eclipsebio),a leading RNA genomics company developing […]

read more

Press Release

01
17
23

Eclipsebio Announces Publication of New Method to Optimize and Scale the Detection of RNA-Binding Protein Sites to Accelerate the Understanding of RNA Regulation

An optimized eCLIP technology, named antibody-barcode eCLIP (ABC), increases the number of RNA-binding protein interactomes detected in a single experiment SAN DIEGO, January 17, 2023 – Eclipse Bioinnovations (Eclipsebio), a leading RNA genomics company developing and commercializing novel, data-driven technologies that interrogate RNA, today announced new research demonstrating the optimization of Eclipsebio’s industry-standard eCLIP technology to improve […]

read more